Pharmacy Search
Pharmacy Pharmacy
Most Read Articles
Every-2-month cabotegravir + rilpivirine feasible for HIV treatment
Pearl Toh, 5 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Hydroxychloroquine plus azithromycin may help cure COVID-19 patients
Stephen Padilla, 2 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Genome-wide association study in HK highlights value of drug repositioning in treatment of psychiatric disorders
Dr. Joseph Delano Fule Robles, 04 Sep 2017

A recent genome-wide association study (GWAS) performed by investigators from the Chinese University of Hong Kong (CUHK) has found potential new indications for existing drugs for the treatment of various psychiatric disorders. 
Losartan does not reduce inflammation, fibrosis in HIV patients
Audrey Abella, 6 days ago
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.

Podcast: Assoc Prof Yeo Khung Keong talks about the hopes and promises of AI in cardiology

18 Nov 2019
Podcast: Assoc Prof Yeo Khung Keong talks about the hopes and promises of AI in cardiology
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Every-2-month cabotegravir + rilpivirine feasible for HIV treatment
Pearl Toh, 5 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Hydroxychloroquine plus azithromycin may help cure COVID-19 patients
Stephen Padilla, 2 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Genome-wide association study in HK highlights value of drug repositioning in treatment of psychiatric disorders
Dr. Joseph Delano Fule Robles, 04 Sep 2017

A recent genome-wide association study (GWAS) performed by investigators from the Chinese University of Hong Kong (CUHK) has found potential new indications for existing drugs for the treatment of various psychiatric disorders. 
Losartan does not reduce inflammation, fibrosis in HIV patients
Audrey Abella, 6 days ago
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.